ARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway
ARPC1B emerges as an essential oncogenic factor in ccRCC by stimulating EMT and activating the Wnt/β-catenin pathway, ultimately enhancing tumor aggressiveness and metastatic potential. Thus, targeting ARPC1B represents a promising therapeutic strategy, warranting further exploration in ccRCC management.
Authors
- Yi‐Jun Xue
- Yumin Zhuo (ORCID: https://orcid.org/0000-0002-1236-8203)
- Xiaoqi Lin (ORCID: https://orcid.org/0000-0002-0760-3950)
- Kai Han (ORCID: https://orcid.org/0000-0002-6302-5366)
- Zhiyong Li (ORCID: https://orcid.org/0000-0002-9062-548X)
- Zhen Cai (ORCID: https://orcid.org/0000-0001-6026-3804)
- Jiayin Peng
- Yutong Li (ORCID: https://orcid.org/0000-0003-1141-2214)
Institutions
- Central People's Hospital of Zhanjiang (CN)
- First Affiliated Hospital of Jinan University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.067340
- Citations
- 1
- Primary Topic
- Biological Research and Disease Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.81